Women with HER2-positive metastatic breast cancer in British Columbiawill now be able to access a new treatment option through the BC Cancer Agency.  The BC Cancer Systemic Therapy Program has approved the addition of Kadcyla (trastuzumab emtansine) to be added to the BCCA Drug Benefit Listing. Kadcyla has been approved as second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, who have received prior treatment with Herceptin (trastuzumab) plus chemotherapy in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with trastuzumab plus chemotherapy.

"We're pleased British Columbia has added Kadcyla to the provincial formulary, giving patients with HER2-positive metastatic breast cancer in the province access to an important option to treat their disease," said Mr. Ronnie Miller, president and CEO, Roche Canada. "Roche has a long history of research and development in oncology, and we are proud to offer a new and targeted way of treating HER2-positive breast cancer."

For more details, go to: http://www.newswire.ca/en/story/1352071/bc-cancer-agency-adds-kadcyla-to-the-provincial-formulary-fo...